ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

NCI Funding Plan For 1983: 20% Cut From Recommended Levels for All Grants, Change In Program Projects

October 8, 1982

Advisers Discuss What To Do About Physician-Scientists

May 1, 1992

NIH Biennial Report Offers Research Portrait

September 24, 2010

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

December 28, 2012

Doctor-Patient Interaction May Cause Racial Disparity

February 24, 2006

UICC Announces Grant Programs to Continue

April 15, 1977